Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred

We show how the use and interpretation of population-based cancer survival indicators can help oncologists talk with breast cancer (BC) patients about the relationship between their prognosis and their adherence to endocrine therapy (ET). The study population comprised a population-based cohort of e...

Descripción completa

Detalles Bibliográficos
Autores: Font, Rebeca, Buxó Pujolràs, Maria, Ameijide, Alberto, Martínez, José Miguel, Marcos-Gragera, Rafael, Carulla, Marià, Puigdemont, Montserrat, Vilardell, Mireia, Civit, Sergi, Viñas, Gemma, Espinàs, Josep Alfons, Galceran, Jaume, Izquierdo i Font, Àngel Xavier, Borràs Andrés, Josep Maria, Clèries, Ramon
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10256/21492
Acceso en línea:http://hdl.handle.net/10256/21492
Access Level:acceso abierto
Palabra clave:Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Hormonoteràpia
Hormone therapy
id ES_fadb235c8c0acfb01162c273e367ea3f
oai_identifier_str oai:recercat.cat:10256/21492
network_acronym_str ES
network_name_str España
repository_id_str
spelling Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPredFont, RebecaBuxó Pujolràs, MariaAmeijide, AlbertoMartínez, José MiguelMarcos-Gragera, RafaelCarulla, MariàPuigdemont, MontserratVilardell, MireiaCivit, SergiViñas, GemmaEspinàs, Josep AlfonsGalceran, JaumeIzquierdo i Font, Àngel XavierBorràs Andrés, Josep MariaClèries, RamonMama -- Càncer -- TractamentBreast -- Cancer -- TreatmentHormonoteràpiaHormone therapyWe show how the use and interpretation of population-based cancer survival indicators can help oncologists talk with breast cancer (BC) patients about the relationship between their prognosis and their adherence to endocrine therapy (ET). The study population comprised a population-based cohort of estrogen receptor positive BC patients (N = 1268) diagnosed in Girona and Tarragona (Northeastern Spain) and classified according to HER2 status (+ / −), stage at diagnosis (I/II/III) and five-year cumulative adherence rate (adherent > 80%; non-adherent ≤ 80%). Cox regression analysis was performed to identify significant prognostic factors for overall survival, whereas relative survival (RS) was used to estimate the crude probability of death due to BC (PBC). Stage and adherence to ET were the significant factors for predicting all-cause mortality. Compared to stage I, risk of death increased in stage II (hazard ratio [HR] 2.24, 95% confidence interval [CI]: 1.51–3.30) and stage III (HR 5.11, 95% CI 3.46–7.51), and it decreased with adherence to ET (HR 0.57, 95% CI 0.41–0.59). PBC differences were higher in non-adherent patients compared to adherent ones and increased across stages: stage I: 6.61% (95% CI 0.05–13.20); stage II: 9.77% (95% CI 0.59–19.01), and stage III: 22.31% (95% CI 6.34–38.45). The age-adjusted survival curves derived from this modeling were implemented in the web application BreCanSurvPred (https://pdocomputation.snpstats.net/BreCanSurvPred). Web applications like BreCanSurvPred can help oncologists discuss the consequences of non-adherence to prescribed ET with patientsTis work was supported by Instituto de Salud Carlos III PI18/01836 funded by FEDER funds/European Regional Development Fund (ERDF)-a way to Build Europe-//FONDOS FEDER “una manera de hacer Europa”. We also acknowledge the support of Agència d’Avaluació d’Universitats i Recerca (2017SGR00735) from Generalitat de Catalunya and PGC2018-095931-B-100 (MCIU/AEI/FEDER, UE). We also thank CERCA Programme/Generalitat de Catalunya for institutional supportNature Research2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionpeer-reviewedapplication/pdfhttp://hdl.handle.net/10256/21492Scientific Reports, 2022, vol. 12, art.núm. 8097Articles publicats (D-I)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglésinfo:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-12228-yinfo:eu-repo/semantics/altIdentifier/eissn/2045-2322Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10256/214922026-05-29T05:05:01Z
dc.title.none.fl_str_mv Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
title Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
spellingShingle Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
Font, Rebeca
Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Hormonoteràpia
Hormone therapy
title_short Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
title_full Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
title_fullStr Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
title_full_unstemmed Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
title_sort Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
dc.creator.none.fl_str_mv Font, Rebeca
Buxó Pujolràs, Maria
Ameijide, Alberto
Martínez, José Miguel
Marcos-Gragera, Rafael
Carulla, Marià
Puigdemont, Montserrat
Vilardell, Mireia
Civit, Sergi
Viñas, Gemma
Espinàs, Josep Alfons
Galceran, Jaume
Izquierdo i Font, Àngel Xavier
Borràs Andrés, Josep Maria
Clèries, Ramon
author Font, Rebeca
author_facet Font, Rebeca
Buxó Pujolràs, Maria
Ameijide, Alberto
Martínez, José Miguel
Marcos-Gragera, Rafael
Carulla, Marià
Puigdemont, Montserrat
Vilardell, Mireia
Civit, Sergi
Viñas, Gemma
Espinàs, Josep Alfons
Galceran, Jaume
Izquierdo i Font, Àngel Xavier
Borràs Andrés, Josep Maria
Clèries, Ramon
author_role author
author2 Buxó Pujolràs, Maria
Ameijide, Alberto
Martínez, José Miguel
Marcos-Gragera, Rafael
Carulla, Marià
Puigdemont, Montserrat
Vilardell, Mireia
Civit, Sergi
Viñas, Gemma
Espinàs, Josep Alfons
Galceran, Jaume
Izquierdo i Font, Àngel Xavier
Borràs Andrés, Josep Maria
Clèries, Ramon
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Hormonoteràpia
Hormone therapy
topic Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Hormonoteràpia
Hormone therapy
description We show how the use and interpretation of population-based cancer survival indicators can help oncologists talk with breast cancer (BC) patients about the relationship between their prognosis and their adherence to endocrine therapy (ET). The study population comprised a population-based cohort of estrogen receptor positive BC patients (N = 1268) diagnosed in Girona and Tarragona (Northeastern Spain) and classified according to HER2 status (+ / −), stage at diagnosis (I/II/III) and five-year cumulative adherence rate (adherent > 80%; non-adherent ≤ 80%). Cox regression analysis was performed to identify significant prognostic factors for overall survival, whereas relative survival (RS) was used to estimate the crude probability of death due to BC (PBC). Stage and adherence to ET were the significant factors for predicting all-cause mortality. Compared to stage I, risk of death increased in stage II (hazard ratio [HR] 2.24, 95% confidence interval [CI]: 1.51–3.30) and stage III (HR 5.11, 95% CI 3.46–7.51), and it decreased with adherence to ET (HR 0.57, 95% CI 0.41–0.59). PBC differences were higher in non-adherent patients compared to adherent ones and increased across stages: stage I: 6.61% (95% CI 0.05–13.20); stage II: 9.77% (95% CI 0.59–19.01), and stage III: 22.31% (95% CI 6.34–38.45). The age-adjusted survival curves derived from this modeling were implemented in the web application BreCanSurvPred (https://pdocomputation.snpstats.net/BreCanSurvPred). Web applications like BreCanSurvPred can help oncologists discuss the consequences of non-adherence to prescribed ET with patients
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
peer-reviewed
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10256/21492
url http://hdl.handle.net/10256/21492
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-12228-y
info:eu-repo/semantics/altIdentifier/eissn/2045-2322
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientific Reports, 2022, vol. 12, art.núm. 8097
Articles publicats (D-I)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425276064104448
score 15,812429

Similares en LA Referencia